Fig. 5: The organ distribution of anti-Mb RabMAb in RM/CS-AKI mice.
From: Rescue RM/CS-AKI by blocking strategy with one-dose anti-myoglobin RabMAb
a In vivo fluorescence imaging of RM/CS-AKI mice treated with single intravenous administration of Cy5 and Cy5 labeled anti-Mb RabMAb (1 mg/kg) at different time points (0.5 h, 6 h, 12 h, 24 h, 3 d, 5 d, 7 d and 14 d). n = 3 for biological replicates per group. b Fluorescence images of major organs of RM/CS-AKI mice treated with single intravenous administration of Cy5 and Cy5 labeled anti-Mb RabMAb (1 mg/kg) at different time points (1 d, 3 d, 5 d, 7 d, and 14 d). n = 3 for biological replicates per group. c–e The fluorescence intensity in the kidney, muscle, and heart after the mice injected with Cy5 and Cy5 labeled anti-Mb RabMAb (1 mg/kg) at different time points (1 d, 3 d, 5 d, 7 d, and 14 d). n = 3 for biological replicates per group. Results are presented as means ± SD. f The plasma concentration-time profiles of anti-Mb RabMAb after a single dose i.v. administration in mice. g Mean pharmacokinetic parameters ( ± standard deviation (S.D.)) of anti-Mb RabMAb after single dose i.v. administration in mice. T1/2, terminal half-life; Tmax, the time to reach maximum plasma concentration; Cmax, the maximum plasma concentration; AUC(inf), the area under the serum concentration-time curve from time 0 to infinity; Vz, the volume of distribution; CI, plasma clearance. Experiments were conducted independently with six mice in each group in (f, g). The data points of 0.5 h, 1 h, 3 h, 6 h, and 12 h for n = 3 biological replicates with 2 technical replicates in each group. The data points of 24 h, 72 h, 120 h, 168 h, 240 h, and 336 h for n = 6 biological replicates in each group. Results are presented as means ± SD. Source data are provided as a Source data file.
